« EDC calls for 'life sciences incubator' | Main | New airport chief to visit tomorrow »

January 15, 2008

Analyst: Alexion will just miss Wall St. forecast

Alexion Pharmaceuticals Inc. is expected to have just missed Wall Street projections for its fourth-quarter earnings, with a loss of 50 cents per share, compared with estimates of a loss of 48 cents per share, Credit Suisse analyst Michael Aberman told the Associated Press.

The stock jumped 86 percent in 2007, the AP reported.

Alexion has spent nearly $80 million renovating the former Dow Chemical plant in Smithfield, where it hopes to produce the drug Soliris, its only commercial product.

Posted by Benjamin N. Gedan  at 2:43 PM | Permalink

Comments

Post a comment

Please be civil. Vicious comments, personal attacks and profanity won't be published. Name and email are required; email address will not publish.

Name:

Email Address:

URL:
Remember Me? YesNo

Comments: (you may use HTML tags for style)

Please type the security code below into the form.